SCHEMBL1892434

SCHEMBL1892434

CC1(C)CN(S(=O)(=O)c2cc(F)cc(F)c2)Cc2c(NC(=O)c3ccccc3NC(=O)[C@@H]3CCCO3)n[nH]c21

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.45
SMN1; SMN2 Q16637 6/20 0.43
RAB9A P51151 4/20 0.43
NPC1 O15118 3/20 0.43
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 3/20 0.42
PAK4 O96013 2/20 0.42
IGF1R P08069 3/20 0.41
NTRK1 P04629 2/20 0.40
POLB P06746 1/20 0.40
PKM P14618 1/20 0.40
PRKCB P05771 2/20 0.39
MEN1 O00255 1/20 0.38
GAA P10253 1/20 0.38
KMT2A Q03164 1/20 0.38
CCNA2 P20248 1/20 0.38
CDK2 P24941 1/20 0.38
CCNA1 P78396 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1883266 1.00 LMNA (0.45) LMNASMN1; SMN2RAB9ANPC1ALDH1A1
SCHEMBL1891450 0.91 IGF1R (0.39) LMNASMN1; SMN2ALDH1A1KDM4EPAK4
SCHEMBL1886919 0.91 PAK4 (0.40) LMNASMN1; SMN2ALDH1A1KDM4EPAK4
SCHEMBL1888704 0.91 PAK4 (0.40) LMNASMN1; SMN2ALDH1A1KDM4EPAK4
SCHEMBL1885525 0.91 IGF1R (0.39) LMNASMN1; SMN2ALDH1A1KDM4EPAK4
SCHEMBL1886922 0.91 PAK4 (0.40) LMNASMN1; SMN2ALDH1A1KDM4EPAK4
SCHEMBL1892362 0.91 PRKCB (0.39) LMNAALDH1A1KDM4EPAK4IGF1R
SCHEMBL1885528 0.91 IGF1R (0.39) LMNASMN1; SMN2ALDH1A1KDM4EPAK4
SCHEMBL1886827 0.91 PRKCB (0.39) LMNAALDH1A1KDM4EPAK4IGF1R
SCHEMBL1889568 0.91 NTRK1 (0.39) LMNASMN1; SMN2ALDH1A1KDM4EPAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-09-22 US disclosed
US-7947686-B2 Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K3, MAP3K1, MAP3K19 LMNA 3253/4885SMN1; SMN2 3711/4885RAB9A 1056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.